OABI vs ZYME
OABI: OmniAb provides a proprietary, AI-enhanced transgenic animal platform that accelerates the discovery of human antibody therapeutics for global pharmaceutical and biotech partners. ZYME: A biotech company pioneering multispecific antibodies and ADCs for cancer and autoimmune disease, monetizing through a partnership-driven royalty aggregation model while advancing an internal pipeline.
Side-by-side fundamentals
| Metric | OABI | ZYME | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $2.24 | $23.13 | |
| Market cap as of 2026-08-08 | $325M | $1.7B | |
| Net margin as of 2026-08-08 | -187.6% | -126.3% | ZYME higher |
| Gross margin as of 2026-08-08 | +98.9% | n/a | |
| Operating margin as of 2026-08-08 | -200.3% | -140.3% | ZYME higher |
| ROE as of 2026-08-08 | -20.3% | -37.8% | OABI higher |
| ROA as of 2026-08-08 | -18.1% | -25.2% | OABI higher |
| Debt / equity as of 2026-08-08 | 0.00 | 1.51 | OABI lower |
| Revenue growth (YoY) as of 2026-08-08 | +8.2% | +3.3% | OABI higher |
| Revenue CAGR (3y) SEC XBRL | -31.9% | -36.4% | OABI higher |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-08-08 | 0.47 | 1.12 | |
| 1-year return as of 2026-08-06 close | +16.1% | +86.4% | ZYME higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.